Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03310359 · ClinicalTrials.gov registry record · NA
Clinical Trial of Anti-oxidant Astaxanthin in Insulin-resistant Subjects
A NA study, sponsored by University of California, San Diego.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
NCT03310359: Completed NA study, sponsored by University of California, San Diego.
NCT03310359 is a NA study that has completed, run by University of California, San Diego. The registered enrollment target is 34 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03310359, a NA study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
Study Summary
Astaxanthin is a natural compound, present in many foodstuffs and available as a nutritional supplement that has been shown to have beneficial effects on many of the features of insulin resistance/glucose intolerance, at least in animals. The goal of this project is to provide a validation of astaxanthin effects on metabolic regulation in humans and their mechanism(s) of action, to determine if astaxanthin could have any value as a "neutraceutical" to help improve regulation of glucose and fat metabolism in subjects with insulin resistance/ glucose intolerance.
Primary Outcome
Change from baseline insulin sensitivity during hyperinsulinemic/euglycemic clamp at 6 months.
Interventions
- DIETARY_SUPPLEMENT Astaxanthin
- OTHER Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-07 |
| Est. Completion | 2022-12-31 |
| Phase | NA |
What the finished NCT03310359 record still lists
NCT03310359 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Astaxanthin is the first listed.
NCT03310359 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03310359 about?
NCT03310359 is a clinical study titled "Clinical Trial of Anti-oxidant Astaxanthin in Insulin-resistant Subjects". Astaxanthin is a natural compound, present in many foodstuffs and available as a nutritional supplement that has been shown to have beneficial effects on many of the features of insulin resistance/glucose intolerance, at least in animals. The goal of this project is to provide a validation of astaxa...
What is the current status of trial NCT03310359?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2016-07. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT03310359?
The interventions under investigation include: Astaxanthin (DIETARY_SUPPLEMENT), Placebo (OTHER).
Who is sponsoring clinical trial NCT03310359?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03310359's enrollment target sits among peer trials
34 1570th of 2000 higher than 427 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia